Amgen reports 58 percent result as Oppenheimer raises target for Amgen stock

Published on 10/27/2026 at 11:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Oppenheimer raised its target from USD 450.00 to USD 480.00 on October 23, 2026. Amgen stock has third-quarter results scheduled for November 3, 2026.

Clinical results and analyst targets

Amgen reported a 58 percent reduction in death risk for Imdelltra with Imfinzi on October 24, 2026.
Oppenheimer raised its Amgen target from USD 450.00 to USD 480.00 on October 23, 2026.
Amgen stock traded at EUR 398.60 at 11:08 a.m. CEST at Lang & Schwarz on October 27, 2026.

Amgen, US0311621009, Illustration mit AI erstellt.

Amgen Inc. (ISIN US0311621009) was trading at EUR 398.60 at Lang & Schwarz on October 27, 2026 at 11:08 a.m. CEST. The company had reported on October 24 that Imdelltra combined with Imfinzi reduced the risk of death by 58 percent in first-line extensive-stage small-cell lung cancer, according to Amgen.

Oncology data lead the update

The result is the latest dated company event in the available investor-relations calendar. It links Amgen's stock story to clinical execution rather than to a reported earnings figure, with the 58 percent risk reduction presented at the ESMO Congress 2026.

Amgen had also said on October 20 that Tezspire delivered histologic remission and symptom improvement in eosinophilic esophagitis, while its foundation reported on October 22 that it had topped USD 75.00 million in biotechnology education support and reached 100,000 students, according to Amgen.

What does the target change signal?

Oppenheimer analyst Jay Olson raised the price target from USD 450.00 to USD 480.00 on October 23, 2026, while keeping an Outperform rating, as reported by Markets Insider. The note cited Tezspire, MariTide, dazodalibep and Imdelltra as drivers in the analyst's outlook.

Three dated developments

On October 20, 2026, Amgen highlighted Tezspire results in eosinophilic esophagitis; on October 22, 2026, the Amgen Foundation cited USD 75.00 million in support and 100,000 students reached; on October 24, 2026, Amgen presented the Imdelltra and Imfinzi result with a 58 percent reduction in death risk. Each event carries a distinct operating or clinical figure.

Next reporting date

Amgen's third-quarter 2026 results are scheduled for November 3, 2026, according to Investing.com. That release will provide the next test of prescription trends and financial performance after the second-quarter revenue of USD 10.05 billion reported for the period ended June 30, 2026.

Stock valuation context

Amgen's market capitalization was USD 240.4 billion as of October 26, 2026. The primary NASDAQ listing showed a 52-week range of USD 288.00 to USD 450.98, placing the latest US-market reference below the upper end of that range.

Amgen stock was trading at EUR 398.60 at Lang & Schwarz on October 27, 2026 at 11:08 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Amgen stock.